Bahamas vs Congo, Democratic Republic of the: Access to anti-retroviral drugs, male
Bahamas
74.0%
in 2024
Congo, Democratic Republic of the
75.0%
in 2024
Bahamas rank
58th
Congo, Democratic Republic of the rank
55th
Access to anti-retroviral drugs, male over time
- Bahamas
- Congo, Democratic Republic of the
How they compare
Congo, Democratic Republic of the currently reports 75.0% against 74.0% in Bahamas, a difference of 1.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Congo, Democratic Republic of the ahead.
Bahamas ranks 58th and Congo, Democratic Republic of the ranks 55th of 141 countries.
Bahamas has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bahamas | Congo, Democratic Republic of the | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 16.9% | 1.9% | 15.0% | Bahamas |
| 2010s | 47.5% | 19.5% | 28.0% | Bahamas |
| 2020s | 71.8% | 68.0% | 3.8% | Bahamas |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Bahamas or Congo, Democratic Republic of the?
- Congo, Democratic Republic of the, at 75.0% against 74.0% in Bahamas as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Bahamas and Congo, Democratic Republic of the?
- 1.0%, with Congo, Democratic Republic of the ahead.
- How many years of comparable data are there for Bahamas and Congo, Democratic Republic of the?
- 25 years are reported by both, from 2000 to 2024.
- How do Bahamas and Congo, Democratic Republic of the rank globally for access to anti-retroviral drugs, male?
- Bahamas ranks 58th and Congo, Democratic Republic of the ranks 55th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.